Publications by authors named "Nuria Moragas"

Background: A better understanding of ductal carcinoma in situ (DCIS) is urgently needed to identify these preinvasive lesions as distinct clinical entities. Semaphorin 3F (SEMA3F) is a soluble axonal guidance molecule, and its coreceptors Neuropilin 1 (NRP1) and NRP2 are strongly expressed in invasive epithelial BC cells.

Methods: We utilized two cell line models to represent the progression from a healthy state to the mild-aggressive or ductal carcinoma in situ (DCIS) stage and, ultimately, to invasive cell lines.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the mechanisms behind resistance to HER2-targeted therapies in breast cancer, focusing on the role of tumor-associated fibroblasts (TAFs).
  • TAFs contribute to therapy resistance by producing FGF5, which activates FGFR2 in nearby cancer cells, leading to HER2 activation and a feedback loop that intensifies tumor aggressiveness.
  • Targeting FGFR2 with inhibitors not only blocks HER2 activation but also prompts cell death in resistant cells, suggesting a potential therapeutic strategy to overcome resistance in HER2-positive breast cancer patients.
View Article and Find Full Text PDF

Background: The microenvironment and stress factors like glucocorticoids have a strong influence on breast cancer progression but their role in the first stages of breast cancer and, particularly, in myoepithelial cell regulation remains unclear. Consequently, we investigated the role of glucocorticoids in ductal carcinoma in situ (DCIS) in breast cancer, focusing specially on myoepithelial cells.

Methods: To clarify the role of glucocorticoids at breast cancer onset, we evaluated the effects of cortisol and corticosterone on epithelial and myoepithelial cells using 2D and 3D in vitro and in vivo approaches and human samples.

View Article and Find Full Text PDF

Histamine receptor 1 (HRH1) belongs to the rhodopsin-like G-protein-coupled receptor family. Its activation by histamine triggers cell proliferation, embryonic development, and tumor growth. We recently established that HRH1 is up-regulated in basal and human epidermal growth factor receptor 2 (HER2)-enriched human breast tumors and that its expression correlates with a worse prognosis.

View Article and Find Full Text PDF